tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

RxSight sees FY25 revenue $120M-$130M, consensus $126.37M

Gross margin in the range of 72% to 74%, representing an implied increase of 130 basis points to 330 basis points compared to 2024; Operating expenses in the range of $145.0 million to $155.0 million, representing an implied increase of 7% to 14% compared to 2024; and Operating expenses include non-cash stock-based compensation expense in the range of $27.0 million to $30.0 million.

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1